Virginia Felouzis, Patricia Hermand, Guy Trambly de Laissardière, Christophe Combadière, Philippe Deterre. Comprehensive analysis of chemokine-induced cAMP-inhibitory responses using a real-time luminescent biosensor. Cellular Signalling, Elsevier, 2015, 28 (1) 
Comprehensive analysis of chemokine-induced cAMP-inhibitory responses using a real-time luminescent biosensor

Introduction
Chemokines (CHKs) are secreted, soluble molecules expressed by numerous immune cell types, either constitutively or induced under inflammatory conditions. They play a central role in cell recruitment and positioning in the immune system and during development. CHK signaling is crucial to the inflammatory process and is dysregulated in autoimmune disorders, rheumatologic diseases, and atherosclerosis [1, 2] . CHK receptors are members of the G-protein-coupled receptor (GPCR) family, specifically the rhodopsin class, coupled to the Gi class of G-proteins. However, some CHK receptors were recently found coupled to the Gq class [3] . The Gi-mediated cAMPinhibitory responses to CHK were evidenced a long time ago, as early as calcium responses [4] ; however, their functional role remains controversial. Some studies have indicated a regulatory role for the cAMP messenger in monocyte chemotaxis towards CCL2 [5] , while others have suggested a positive role [6] or no role at all [7] . Therefore, the precise real-time mechanism of CHK-triggered cAMP signaling is still unknown.
Recent use of FRET biosensors [8] [9] [10] [11] [12] has unraveled subtle kinetic information about cAMP cellular signaling and the unexpected compartmentation and diffusional restrictions of cAMP and its signaling partners [13] [14] [15] . Most of these studies were done with cAMP-stimulatory ligands, such as adrenergic molecules in cardiomyocytes [15] or dopaminergic neuronal responses [16] , and rarely addressed the Gi-mediated cAMP-inhibitory signals, such as those evoked by CHKs.
In this study, we investigated the CHK-induced cAMP-inhibitory responses downstream of CX3CR1 and CXCR4 by measuring cellular cAMP in real time using the GloSensor TM biosensor. We found that the response kinetics were remarkably conserved with all modes of cAMP prestimulation (forskolin and Gs-associated ligands) and that the period between the additions of the pre-stimulatory ligand and CHK did not affect the response, indicating the robustness of CHK action in diverse inflammatory contexts.
Material and methods
Reagents
Cell culture media was purchased from Gibco, Life Technologies. FBS was obtained from Dutscher Scientific (Les Ulis, France). Forskolin (FSK), 3-isobutyl-1-methylxanthine (IBMX), prostaglandin E2 (PGE2), hygromycin B, and geneticin (G418) were from Sigma-Aldrich. Pertussis toxin was purchased from Enzo Life Sciences. Dynasore was obtained from Calbiochem (Merck Millipore; Guyancourt, France). The 96-well clear-bottomed white microplates were from Greiner-Bio-One (Dutscher Scientific; Les Ulis, France). JetPEI was purchased from Ozyme (Montigny-le Bretonneux, France). The Dual-Luciferase® reporter assay system, pGloSensor TM -22F-cAMP plasmid, and GloSensor TM cAMP reagent were purchased from Promega (Charbonnière, France). The CX3CL1 CHK domain and CX3CL1 full-length protein were from R&D Systems (Lille, France), and CXCL12, CXCL26, and CCL2 were from Peprotech (Neuilly sur Seine, France). Mouse monoclonal antibodies against human CX3CR1 and CXCR4 conjugated with allophycocyanin (APC) or phycoerythrin (PE) and IgG1and IgG2B isotype controls were from R&D Systems (Lille, France). Sp-8-br-cAMP was from BioLog Life Science Institute (Bremen, Germany)
Cell culture
HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) plus GlutaMAX I supplemented with 10% FBS, 1 mM sodium pyruvate and 1% penicillin and streptomycin. Human HEK293 cells expressing the human CX3CR1 gene [18] were transfected with a plasmid encoding an engineered cAMP-sensitive luciferase gene (pGloSensorTM-22F-cAMP plasmid, Promega) using the jetPEI method (Polyplus, Ozyme). A stable clone (called HEKgloCX3CR1) was selected for their ability to respond to FSK. The HEKgloCX3CR1 cells were grown in supplemented DMEM as above plus geneticin (0.5 mg/mL) and hygromycin (0.1 mg/mL).
HBP-ALL and Jurkat cell lines were maintained in Roswell Park Memorial Institute medium (RPMI-1640) supplemented with 10% FBS. A stable HPB-ALL clone expressing CX3CR1 was made, as previously described [17] . Prior to electroporation, the cells were washed with phosphatebuffered saline (PBS), counted, and resuspended in RPMI-1640 FBS-free media at a cell density of 5 × 10 6 cells/400 µL in a 4 mm Gene Pulser® cuvette (Bio-Rad; Hercules, CA) and mixed with 10 µg of the pGloSensor TM -22F-cAMP plasmid. After 10 min at room temperature, a single electrical pulse at 270 V and a capacitance of 950 µF was delivered. The cell suspension was transferred to pre-warmed culture media and incubated for 24 h at 37°C in a humidified atmosphere of 5% CO 2 .
GloSensor assay
The day before the experiment, cells expressing the biosensor were seeded into a 96-well clearbottomed white microplate in culture medium (100 µL per well) and incubated at 37°C, 5% CO2 overnight. The culture medium was then replaced with CO 2 -independent medium containing a 2% v/v GloSensor cAMP reagent stock solution and 10% FBS. After 90 min of incubation at 37°C, the luminescence was measured using a TriStar plate reader (Berthold Technologies; Thoiry, France; 100 ms integration). The luminescence was recorded before and after injection of the drugs (FSK, CHK, and vehicle).
RESULTS
cAMP-inhibitory response to CHK is independent of the method of cAMP prestimulation (forskolin, inhibitor of phosphodiesterase, Gs-linked ligands)
To explore the CHK-induced cAMP-inhibitory response, we stably expressed the luminescent biosensor GloSensor TM -22F in a HEK293 cell clone that constitutively expressed CXCR4 and ectopically expressed CX3CR1 [18] . The HEK biosensor-expressing subclone -hereafter called HEKgloCX3CR1 -exhibited a stimulatory response to FSK, a classic adenylate cyclase (AC) activator [19] ( Figure 1A , black trace). As expected, the FSK response was absent when using the parental HEK293 clone that does not express the biosensor ( Figure 1A , dotted trace). To examine the cAMP-inhibitory responses, the CHK was added at the peak of the FSK signal ( Figure 1A , thin arrow). Using 100 nM of either CX3CL1 ( Figure 1A , red traces) or CXCL12 ( Figure 1A , green traces), we observed a significant inhibition of the signal, while the addition of the control CHK CCL2 left the cAMP response unchanged ( Figure 1A , blue trace). The net response after addition of either of the three CHKs -i.e. difference between signals obtained in the presence ( Figure 1A , blue, red and green traces) and absence of CHKs ( Figure 1A , black trace) -is reported in Figure 1B (left side ordinate). Both CX3CL1 and CXCL12 signals reached a maximum peak 8-12 min after CHK addition and displayed a slow decay, with 50% of the peak amplitude after 40-50 min. When expressed as a percentage of the maximum FSK control response ( Figure 1B , right side ordinate), the amplitudes of the signals from both CX3CL1 and CXCL12 treatments were approximately 35-40% (Table 1) . While the native, soluble form of CX3CL1 is not only composed of the CHK domain, as with other CHKs like CXCL12, but also a mucin stalk [20] , we checked whether the full-length, soluble CX3CL1 evoked a response similar to the CX3CL1 CHK domain ( Figure S1 ).
We next examined whether the response was conserved if CHK was added at a shorter time after FSK. We observed that the CX3CL1 response had a similar amplitude and shape when the CHK was added either 10 ( Figures 1C, blue Figures 1A and S2A ). This was surprising since a long-term weakening of the FSK action was never reported. However, such decay has already been observed in long-term FSK experiments, using the GloSensor [21, 22] . We noticed that this decay globally followed a hyperbolic curve (i.e. linear when plotted as Log/Log, Figure S2B ), as is often observed in luciferase bioluminescence experiments [23, 24] . So, this hyperbolic decline is probably due to intrinsic properties of the luminescence physical process. Whatever the origin of this long term decay, it was interesting to test the CHK response during its course. So we also added CX3CL1 60 min after FSK and observed a net decrease of the signal ( Figure 1C , green trace). Expressing the CX3CL1 response in this case as a percentage of the control maximum as for the preceding experiments clearly gave a lower amplitude than for preceding responses. By contrast, when we expressed the results as a percentage of the luminescence gained when the CHK was added, the response was similar to the previous ones ( Figure 1C and Table 1 ).
The CHK response was further analyzed as a function of the concentrations of FSK added before CHK treatment. The addition of 0.5, 1, 5, and 20 µM FSK produced signals with amplitudes from 300-4000 luminescence units ( Figure S2A, thin traces) . In each case, CX3CL1 induced a net inhibitory response ( Figure S2A , bold traces). When expressed as a percentage of the maximum control signal, the responses to CX3CL1 were similar when using FSK concentrations of 0.5 or 1 µM ( Figure 1D , black and red traces), with a peak in amplitude at approximately 30%. With higher FSK concentrations, i.e., 5 and 20 µM ( Figure S2A , blue and green traces), the FSK signal was greater than 2000 luminescence units, and the amplitude of the subsequent CHK response was smaller (5-15%) ( Figure 1D , blue and green traces). The distortion observed at the highest FSK concentration was probably due to saturation of the biosensor, as indicated by the GloSensor manufacturer when luminescence exceeds 2000 units and confirmed when we used a permeant, non-hydrolysable cAMP analog ( Figure S3 ). Taken together, our data indicate that the CHK response was robust and did not depend on the concentration of the pre-stimulatory compound or the time point of treatment during pre-stimulation, as long as the signal was kept in the linear range of biosensor activity.
Next, the effect of various CHK doses was analyzed. With all of the concentrations, we observed CX3CL1 responses with similar outlines (Figure 2A ). The dose-response curves had similar EC50s, almost 0.1 nM, with two different FSK concentrations (0.25 and 1 µM) ( Figure 2B ). Moreover, the CX3CL1 responses were suppressed after pertussis toxin treatment ( Figure 2A , grey trace), confirming that the CHK act through the Gi-pathway. Similar results were found with CXCL12 responses (data not shown).
According to previous studies of Gs-mediated cAMP-stimulatory responses [13, 25] , phosphodiesterases (PDEs) are involved in both limiting the amplitude of cAMP responses and promoting their rapid decline. As expected, the addition of IBMX, a non-selective PDE inhibitor, considerably increased the FSK-induced cAMP signal ( Figure S4A , compare red and black thin traces). By contrast, the amplitude of the CX3CL1 response was only slightly decreased as compared to that observed in the absence of IBMX ( Figure S4B , red and black traces; Table 1 ). However, the response kinetics was noticeably slower: the maximum response appeared after more than 25 min (Table 1) . We also analyzed the response to CX3CL1 treatment after addition of IBMX alone ( Figure S4A , blue traces): we detected responses similar to that observed in the presence of FSK plus IBMX ( Figure S4B , blue trace, Table 1 ).
We also tested a more physiological cAMP pre-stimulation, i.e., agonists of the GPCR coupled to Gs, such as the prostaglandin or  2 -adrenergic receptors present in HEK293 cells [26] [27] [28] . Addition of PGE2 to HEKgloCX3CR1 produced a signal similar to that evoked by FSK ( Figure S5A , black trace) while the addition of the  2 -adrenergic agonist isoproterenol generated a signal gaining its maximum in less than 10 minutes and showing biphasic decay ( Figure S5C black trace). The subsequent CHK responses (Figures S5B, S5D) were found to be similar to that observed when FSK was the prestimulatory compound, with comparable amplitude and time to maximum (Table  1) . Finally, we checked the CHK responses were similar in other cell types, such as Jurkat and HPB-ALL (data not shown). Globally our data indicated that the CHK response was relatively independent of the cellular context and the prestimulatory conditions (nature and concentration of the stimulating agent, delay with which CHK is added).
Absence of cross desensitization in different CHK responses
Because different CHKs seem to share the same signaling machinery, we wanted to test whether the addition of one CHK might suppress the subsequent response from another. After a full response to CX3CL1, a second treatment of CX3CL1 gave no signal at all ( Figure 3A , trace a, bold arrows), while a second treatment of CXCL12 gave a clear response ( Figure 3A , trace b, empty arrow). A similar pattern was observed in the reverse scenario, i.e., when CX3CL1 treatment followed CXCL12 ( Figure 3A , trace c). Moreover, when the individual CX3CL1 responses were expressed as a percentage of the control at the time of CHK treatment, the signals were similar, regardless of whether the CX3CL1 was added after CXCL12 ( Figure 3B , green trace corresponding to trace c), or after the control CHK CCL2 ( Figure 3B , yellow trace corresponding to trace d). The same pattern was also found for CXCL12 responses ( Figure 3C corresponding to traces b and e). This indicates that (i) there was no cross desensitization between responses to two different CHKs and (ii) the intracellular machinery was not a limiting factor for the response amplitude of individual CHKs. To confirm this latter result, we simultaneously treated cells with CX3CL1 and CXCL12 ( Figure 3A , trace f). As expected, this produced a greater signal than a single CHK (more than 50%); however, its amplitude did not appear to correspond to the mere addition of both single responses.
Role of receptor internalization in the dynamics of the CHK response
Recently, cellular cAMP responses have been shown to be elicited even when the receptors were internalized in both Gs-mediated responses [29] [30] [31] [32] [33] [34] [35] and Gi-mediated ones [36] . Therefore, we investigated the role of the surface CHK receptors in shaping the cAMP-inhibitory responses. To this end, we used the human CX3CR1 antagonist F1 that we recently identified using intracellular calcium signaling [37] . As expected, F1 was also a competitive antagonist for CX3CL1-evoked cAMP-inhibitory responses ( Figure S6A ): the double-reciprocal plot gave the same intercept in the presence and absence of the inhibitor, a hallmark of competitive inhibition ( Figure S6B ). Addition of a saturating concentration of F1 and CHK effectively suppressed the cAMP response ( Figure 4A , compare traces a and b). When added 8 or 15 min after CX3CL1, the antagonist elicited a rapid return to zero of the signal and shortened the length of the response ( Figure 4A , traces c and d). By contrast, F1 treatment after the response peak -at 30 or 60 min -had no effect ( Figure 4A , traces e and f), indicating that the surface active receptors were not involved in continuing the response. Consistent with this hypothesis, we found that the surface CX3CR1 receptor number decreased 30 min after CX3CL1 treatment and remained stable for 90 min ( Figure 4B , black circles). Next, we used dynasore, an inhibitor of dynamin-mediated receptor internalization [38, 39] . After treatment with this compound, CX3CR1 internalization was completely abolished ( Figure 4B , blue circles). This treatment slightly delayed the onset of the cAMP-inhibitory response, and its decay was significantly slowed down ( Figure 4C , compare blue and black traces).
DISCUSSION
This study demonstrates that the cAMP biosensor is a valuable tool to delineate CHK-induced cAMP-inhibitory responses, particularly downstream of CX3CR1 and CXCR4. Biosensors based on luminescence [40] or FRET techniques [41] [42] [43] [44] [45] have been largely used to decipher the temporal dynamics of Gs- [28, 46, 47] and Gq-mediated [48, 49] cAMP-related activation. However, Gimediated cAMP-inhibitory signals are rarely monitored with these techniques [50] . While some studies have used the 22F-GloSensor TM cAMP-luminescent biosensor to quantify Gi-mediated responses in HEK293 cells, they only used an end-point assay [21, 40] . In this study, we used this biosensor to monitor its kinetics. We primarily found that the responses evoked by CHKs, when expressed as a percentage of cAMP inhibition, were remarkably conserved regarding both their amplitude and kinetics. The CHK response seems limited to 30-40% inhibition, regardless of the manner of cAMP pre-stimulation and time of CHK treatment ( Figure 1B, S5B and S5D ; Table 1 ). The amplitude is of the same order of magnitude as the amplitude of CHK Gi-mediated responses found with conventional cellular cAMP assays [4, 5, 51] . In contrast to most methods that monitor cAMP-inhibitory response, the biosensor technique used here does not require a high concentration of FSK and simultaneous addition of IBMX. This allows measurements to be done in a more physiological context, i.e., in the presence of agonists of native inflammatory Gs-associated receptors ( Figure S5 ). We noticed that the stimulatory response evoked by isoproterenol has a biphasic kinetics ( Figure S5C ) that is not observed with other biosensors in the same cell type [28] . This could be due to receptors differentially distributed in rafts [14, 52] . Anyway, the kinetics of the superimposed Gi-mediated chemokine response remains independent of these various stimulatory signals ( Table 1) .
As expected, the main limiting factor in our observation of CHK-induced cAMP-inhibitory responses was the sensitivity and linear dynamic range of the biosensor: the height of the prestimulation signal had to be small enough to remain in the linear range of the biosensor and avoid saturation (≤ 1 µM FSK, Figure 1D ). These limits globally match the recently described dynamic range of the 22F-GloSensor TM [22] and correspond to a cAMP concentration range of 10 M, as illustrated in Figure S3 (insert).
Another characteristic of this method using GloSensor is the long-term decay of the stimulatory signals observed especially beyond 30 minutes after FSK. This decline could be caused by a loss of cellular ATP, the cofactor of luciferase, after extended cAMP synthesis or/and by a thermal aggregation of the firefly luciferase [24] . More probably it is due to intrinsic properties of the luminescence physical process, since this decay was surprisingly following a hyperbolic curve (i.e., linear when plotted as Log/Log, Figure S2B ) [23, 24] . Anyway, this observed decay does not impair the real-time monitoring of the cAMP-inhibitory response, since the chemokine responses are similar even if chemokine is added 60 minutes after FSK ( Figure 1C , Table 1 ).
Parameters governing the kinetics of the CHK-induced cAMP-inhibitory response
In a cellular context, the activity level of a biosensor, such as the cAMP-related GloSensor used in this study, is controlled by several parameters. One parameter is the apparent affinity of the biosensor binding domain for the cAMP molecule. It is relatively easy to elucidate the on-rate of a cAMP biosensor using permeant and non-hydrolyzable cAMP analogues ( Figure S3) . However, the rate-limiting step of a cAMP-inhibitory response is the off-rate of the cAMP from the biosensor site, and this reaction is harder to test. We found here that the Gi-mediated CHK response peaked after 8-12 min of CHK stimulation; so it is possible that cAMP release from the GloSensor could limit to some extent the onset of the cAMP-inhibitory responses. Moreover, a slow off-rate could account for the fact that the CHK-triggered cellular responses we observed often last 30 min or more. However, such long-time duration was also shown with other Gi-evoked second messengers, for example during extracellular signal-regulated kinase phosphorylation [53] .
Another parameter involved in the dynamic response of the GloSensor is the turnover of the cellular cAMP produced by the ACs and degraded by the PDEs. It is known that the quicker the turnover, the quicker the response of the GloSensor to a drop in the cellular cAMP concentration. This could partly explain why the CHK response in our experiments was slower during both the onset and decline of the cAMP-inhibitory response in the presence of the PDE inhibitor IBMX ( Figure S4 and Table 1 ; see also text below and Figure 6D ).
Compartmentation of cellular cAMP is also a major parameter that governs the shape of the responses monitored using biosensors, as previously shown for cAMP-stimulating responses [54] . Indeed, diverse response kinetics have been observed according to the cellular localization of the biosensor, whether it was soluble or membrane-tethered [9] , or associated in raft or non-raft microdomains [54] . The GloSensor TM 22F used in this study is derived from the PKA-cAMP binding site [22] and is presumably soluble; so it responds to cAMP changes throughout the cytosolic compartment of the cell. If CHK-induced cAMP-inhibitory responses are confined to a subcellular compartment through the co-localization of receptors, Gi-proteins, ACs, and PDEs into a "receptosome", which has been shown for cAMP-stimulatory responses, the signals we observed represent the integration of many local responses, with delayed kinetics and average amplitudes. Use of a membrane-associated biosensor might provide access to such subcellular details [54] .
Regardless of the localization of the biosensor used in this study, we showed that the PDEs had a role in shaping the observed signal. In the presence of the IBMX inhibitor, the FSK signal was increased ten-fold ( Figure S4A , compare red and black traces), and the resting signal increased more than 100-fold ( Figure S4A , blue trace), indicating that the cellular cAMP concentration was a result of basal AC activity vigorously counterbalanced by high PDE activity. One could hypothesize that, similar to Gs-mediated responses whose decay is associated with the activation of PDE [13, 25] , the decay of Gi-mediated CHK responses could be associated with a large inhibition of PDE; however, this is not consistent with our data: the CHK response was only marginally affected by the presence of IBMX ( Figure S4B ; Table 1 ). This indicates that the response decay does not rely on inhibition of IBMX-sensitive PDE activity associated with Gi-mediated AC inhibition. Alternatively, one could suppose that PDEs insensitive to IBMX could exist in HEK293 cells, or that cells could reduce their cellular cAMP in another other way that has yet to be described. Anyway, our data confirmed that the cAMP-inhibitory response evoked by CHK is due to the Gimediated inhibition of the AC activity, either at is basal level ( Figure S4 , blue traces) or at is level stimulated by FSK ( Figure S4 , red and black traces).
The main result from this study is the finding that the amplitude of the CHK response is conserved and approximately 35-40%, regardless of the method used to pre-stimulate the cAMP response. By comparison, a recent study found that responses downstream of metabotropic glutamate receptors assayed with the same biosensor in CHO cells reached an amplitude of 80% [50] . In our study, we showed that the intracellular signaling machinery was not a limiting factor for the response because simultaneous treatment with two different CHKs produced a greater response than individual treatments ( Figure 4A, trace f) . Moreover, sequential treatments with two different CHKs gave two individual responses ( Figure 4A , traces b and c), while sequential treatments with the same CHK resulted in only one response: the receptors became saturated by the first treatment and were unavailable to transduce further signals with the second treatment ( Figure 4A, trace a) . This behavior was reminiscent of the CHK calcium responses [55] and indicates that the number of available surface CHK receptors likely limits the CHK response to 40%. This was further demonstrated with the use of the competitive CX3CL1 antagonist: the amplitude of the response followed the rate of receptor occupancy of the CX3CL1 agonist ( Figure S6 ). Moreover, when the antagonist concentration was sufficient to displace CX3CL1 during the onset of the response, there was a rapid return to the basal signal level ( Figure 4A ), indicating that the number of liganded receptors directly governs the response profile.
The use of biosensors has provoked an important paradigm shift in GPCR signaling, demonstrating that some receptor-induced Gs-mediated cAMP production persists after endosome-induced receptor internalization [29-32, 34, 35] . This has also been shown for a Gi-dependent signals downstream of the sphingosine-1-phosphate receptor 1 [36] . Therefore, it was important to evaluate the potential existence of such signaling from internalized CHK receptors in our model, especially because it is controversial whether this non-classical persistent signaling exists in HEK293 cells [56, 57] . We found that the onset of the CHK response followed the kinetics of internalization (Figure 4) . Moreover, the putative persistent endosomal signaling would be suppressed under conditions where receptor internalization was inhibited [35] : this was clearly not the case here ( Figure 4C ). Therefore, we conclude that the CHK responses we observed are mainly driven by the availability of the cognate surface CHK receptors.
Modeling the CHK response
We attempted to model the global shape of the CHK response using two simple assumptions: (a) the cellular cAMP concentration at each time point is only a function of synthesis by AC and degradation by PDEs and (b) the degradation rate of the PDEs is a linear function of the cAMP concentration at each time point, as for enzymes working in a substrate concentration range equal or less to their K m. . Indeed the K m of PDE4, the main PDE subtype present in HEK293 cells [49, 58] , is of 1µM or above [59] , that is largely higher than the cellular cAMP concentration range here found ( Figure S3 ). We then supposed that the primary cause of the observed signal is exclusively the variations of the AC activity (here denoted ), i.e. either its activation by FSK ( Figure 5A ) or its inhibition by CHK ( Figure 5B ) giving the variations of the cellular cAMP concentration (here denoted C) given in Figures 5C or 5D respectively, according to the following calculations.
So the above assumptions (a) and (b) give the following differential equation (1):
C/t =  -C*  -C/  (1) where C is the cellular cAMP concentration at time t,  the rate of cAMP synthesis by AC in M.min -1 ,  the proportion of cAMP degradation by PDE in min -1 , and   the characteristic time of this cAMP degradation by PDE (  =1/.
Postulating that the addition of FSK at time t 0 results in a rapid increase in the cellular AC activity from  i to  0 ( Figure 5A ), C is given by the following equation (2), as displayed in Figure 5C :
where C 0 is the initial cAMP concentration at time t 0 and C f is the final cAMP concentration, here equal to  0 *  
We then postulated that the addition of a CHK at time t 1 results in a rapid decrease in the cellular AC activity from  0 to p* 0 (0 < p < 1) and that it returns to  1 exponentially with a characteristic time   . Then,  becomes  CHK and is given by the following equation (3), as displayed in Figure  5B :
We can derive the cellular cAMP concentration C CHK for t > t 1 . Assuming that C starts at a constant value C 1 for t ≤ t 1 , we can derive the following equation (4), as displayed in Figure 5D :
Using equation (2), it is possible to fit the data from Figure 1A (black trace), i.e., the second half of the FSK signal onset ( Figure 6A , red trace). Then, we can calculate the CHK response C CHK (t) given by equation (5):
This simple equation that provides C CHK (t) is valid even in the general case where C(t) is not constant for t ≤ t 1 (Supplementary Text S7). Using the   value found by fitting the FSK signal ( Figure 6A , red trace), we were able to calculate the CHK response, e.g. the response obtained when the CHK was added 30 min after FSK stimulation, i.e., at the maximum of the FSK signal. Setting t 1 = t 0 + 30, our model ( Figure 6B , red trace) fits well with the onset of the observed response ( Figure 5B , black trace) and the first half of its decay . We noticed that equation (5), which gives C CHK (t), does not depend on t 0 , i.e., the time point of FSK treatment; it only depends on (t − t 1 ). This means that, according to our model, the outline of the CHK response does not depend on the delay between CHK and FSK treatments. This is exactly what we observed with our experimental data ( Figure 1C ).
However, our present fit (hereafter called model A) did not account for the decay of the FSK signal observed after 20-30 min. This hyperbolic decay ( Figure S2B ) was taken into account (Supplementary text S7) giving a refined model called model B. This model provides a better fit, not only for the FSK signal ( Figure 6A , blue trace), but also for the CHK response ( Figure 6B , blue trace), especially for the second part of the response decline.
Since both models gave similar results for most of the CHK response kinetics, we used model A for further calculations because it is simpler. Using equation (4), we also fit the responses to different CX3CL1 doses (Figure 2A ) by changing the p factor as expected ( Figure 6C ); its value is 0.65, 0.74, 0.79, and 0.85 for the CX3CL1 concentrations of 5, 2.5, 1, and 0.3 nM, respectively. We also fit the CHK response in the presence of IBMX ( Figure S4 , blue trace) by decreasing the  parameter representing the PDE activity: in this case ( Figure 6D ), is more than 2-fold decreased, increasing   from 4.7 ( Figure 6D , red trace) to 10.8 min ( Figure 6D , orange trace). Finally, we used our model to fit the response observed in the presence of dynasore ( Figure 4C , blue trace) by increasing the   parameter, which represents the characteristic time of the return of  to its initial value. Its value increases from 46 ( Figure 6E , red trace) to 250 min ( Figure 6E , orange trace). Taken together, we can conclude that the kinetics of the CHK responses observed with the luminescent biosensor can be reproduced with a simple model of cellular cAMP production and hydrolysis.
Conclusion
As mentioned in the introduction, the contribution of the cAMP second messenger in the functional role of CHKs remains controversial. While it does not seem to be directly involved in chemotaxis [7] , cAMP could either positively [6] or negatively [5, 60] influence the CHK-induced chemotactic activity of monocytes. Moreover, the cAMP-EPAC (exchange protein directly activated by cAMP) pathway seems to contribute to the synthesis of CHKs [61] . The adhesion of monocytes to HUVEC is largely decreased in the presence of cAMP [62, 63] through a mechanism involving PKA and phosphorylated RhoA [64] . By contrast, the cAMP-EPAC pathway stimulates monocyte adhesion in activated HUVEC [6] . Finally, cAMP has been shown to be an important mediator of growth arrest and apoptosis in B and T cells, while it delays apoptosis in neutrophils, likely through EPAC activation [65] . Further work is required to elucidate the functional correlates in the CHK-induced cAMP-inhibitory responses. Nevertheless, the remarkable conservation of the response signal, regardless of the mode of cAMP pre-stimulation, indicates the robustness of the CHK effects, which do not depend on the preceding cellular cAMP level, meaning that each CHK exert their influence in all inflammatory contexts, in a manner independent of others CHKs. Figure 4C , observed in the presence or absence of dynasore pretreatment, were fitted with equation (5) (orange and red traces, respectively). The parameters used were  B = 3.6 for both traces.  1 = 46.0 and p = 0.63 for the red fit and  1 = 250.0 and p = 0.69 for the orange fit. All fits were done using Gnuplot v4.4.
